Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.

Jairath V, Magro F, Protic M, De Hertogh G, Harpaz N, Hisamatsu T, D'Haens G, Pai R, Yu G, Morris N, Luo WT, Hon E, Escobar R, Biedermann L, Reinisch W, VIVID Study Group

Open source

DOI: 10.1093/ecco-jcc/jjag077
Published: 2026 Jun 7
Container: Journal of Crohn's & colitis
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ecco-jcc/jjag077,
  title = {Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.},
  author = {Jairath V and Magro F and Protic M and De Hertogh G and Harpaz N and Hisamatsu T and D'Haens G and Pai R and Yu G and Morris N and Luo WT and Hon E and Escobar R and Biedermann L and Reinisch W and VIVID Study Group},
  year = {2026},
  journal = {Journal of Crohn's \& colitis},
  doi = {10.1093/ecco-jcc/jjag077},
  url = {https://doi.org/10.1093/ecco-jcc/jjag077}
}

RIS

TY  - JOUR
TI  - Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.
AU  - Jairath V
AU  - Magro F
AU  - Protic M
AU  - De Hertogh G
AU  - Harpaz N
AU  - Hisamatsu T
AU  - D'Haens G
AU  - Pai R
AU  - Yu G
AU  - Morris N
AU  - Luo WT
AU  - Hon E
AU  - Escobar R
AU  - Biedermann L
AU  - Reinisch W
AU  - VIVID Study Group
PY  - 2026
JO  - Journal of Crohn's & colitis
DO  - 10.1093/ecco-jcc/jjag077
UR  - https://doi.org/10.1093/ecco-jcc/jjag077
ER  -

APA

V, J., F, M., M, P., G, D. H., N, H., T, H., G, D., R, P., G, Y., N, M., WT, L., E, H., R, E., L, B., W, R., & Group, V. S. (2026). Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.. Journal of Crohn's & colitis. https://doi.org/10.1093/ecco-jcc/jjag077

Source records

pubmed · retrieved 2026-09-26T07:27:23.833Z